

Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule, Oral Liquid), Biologics (API, FDF), Packaging & Labelling, Fill-finish), End Users - Global Forecasts to 2029

Market Report | 2024-08-02 | 385 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global pharmaceutical contract manufacturing market is projected to reach USD 319.6 billion by 2029 from USD 200.9 billion in 2024, at a CAGR of 9.7% during the forecast period of 2024 to 2029. The expansion of the pharmaceutical contract manufacturing market has been primarily propelled by the rising need for generic drugs, which are cost-effective, and the approaching expiration of patents for popular medications. This has compelled companies to prioritize their main functions, leading to increased demand for contract manufacturing services and accelerating the growth of the market.

"The biologics manufacturing services segment is anticipated to experience the highest compound annual growth rate (CAGR) over the period of forecasting that spans from 2024 to 2029."

Based on service, the drug development services, pharmaceutical manufacturing services, biologics manufacturing services, packaging and labelling services, fill-finish services, and other services segment the pharmaceutical contract manufacturing market. It is anticipated that the biologics manufacturing services segment would grow at the highest compound annual growth rate (CAGR) over the period of forecasting in 2024-2029. The growth can be due to the increasing demand for biologics and targeted pharmacological therapies, as well as the rise in the number of studies that are being conducted in the pipeline for cell and gene therapy. Because of these reasons, there is a good chance that segmental growth will be positively affected.

"The growth of the Asia Pacific pharmaceutical contract manufacturing market is likely to be at faster pace during the period of the forecast from 2024-2029."

The segmentations of the pharmaceutical contract manufacturing market include North America, Europe, Asia Pacific, Latin America, and Middle East, and Africa. In 2023, North America accounted for the dominant share of the pharmaceutical contract development and manufacturing market. The dominance of the region is attributable to various factors such as the presence of leading players in the region coupled with the ongoing research activities of pharmaceutical contract Development and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Manufacturing. With increasing awareness about personalized therapeutics, growing initiatives in the region by governments for generics medicines, and the entry of new participants into the pharmaceutical contract development and manufacturing market, the pace of growth in the Asia Pacific region is likely to be faster.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 60% and Demand Side 40%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

- Thermo Fisher Scientific, Inc. (US)
- Catalent, Inc. (US)
- Lonza Group (Switzerland)
- AbbVie, Inc. (US)
- WuXi Apptec (China)
- WuXi Biologics (China)
- Merck KGaA (Germany)
- Siegfried Holding AG (Switzerland)
- Evonik Industries AG (Germany)
- Boehringer Ingelheim International (Germany)
- FUJIFILM Holding Corporation (Japan)
- Samsung Biologics (South Korea)
- Almac Group (UK)
- Vetter Pharma (Germany)
- Alcami Corporation (US)
- Asychem Inc. (China)
- Charles River Laboratories (US)
- Piramal Pharma Solutions (India)
- Syngene (Biocon Limited) (India)
- Delpharm Holdings (France)
- Yuhan Corporation (South Korea)
- Cambrex Corporation. (US)
- Sharp Services, LLC (US)
- Grand River Aseptic Manufacturing (US)
- Jubilant Biosys Ltd. (India)
- Pierre Fabre group (France)
- pfizer centerOne (US)
- Frontage Labs (US)

Research Coverage:

This research report categorizes the pharmaceutical contract manufacturing market by service (drug development services, pharmaceutical manufacturing services (pharmaceutical API manufacturing services, pharmaceutical FDF manufacturing services (parenteral, tablet, capsule, oral liquid, semi-solid, other formulations), biologics manufacturing services (biologics API manufacturing services, biologics FDF manufacturing services), packaging & labelling services, fill-finish services, other services)), end user (big pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, others), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the pharmaceutical contract manufacturing market. A detailed analysis of the key industry players has been done to provide

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

insights into their business overview, services, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the pharmaceutical contract manufacturing market.

Key Benefits of Buying the Report:

The report will assist market leaders and new entrants by providing them with the most accurate estimates of the revenue figures for the entire pharmaceutical contract manufacturing market and its subsegments. Moreover, examining subsegments would improve stakeholders' understanding of the competitive landscape and offer them vital insights to effectively position their company and formulate suitable go-to-market strategies. The objective of this research is to provide stakeholders with a clear understanding of the current market situation. This will be achieved by presenting them with detailed information about the main aspects that impact the industry, such as drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (Increased investment in precision medicines, Patent expiry & increasing demand for generic drugs, High cost of in-house drug development, Investments in advanced manufacturing technologies by CDMOs), restraints (Varying regulatory requirements across various regions), opportunities (Rising demand for cell & gene therapies, Growing inclination toward one-stop-shop model, Market expansion in emerging countries, Growth of nuclear medicine), and challenges (Introduction of serialization, Intellectual property risk) influencing the growth of pharmaceutical contract development and manufacturing market.

- Service Development/Innovation: Thorough investigation of lately launched services available in the pharmaceutical contract manufacturing market.

- Market Development: By means of analysis of regional market trends, the study offers comprehensive knowledge on profitable markets.

- Market Diversification: Comprehensive information on new services, underdeveloped areas, present developments, and pharmaceutical contract manufacturing sector investments is what markets diversification is based on.

- Competitive Assessment: A comprehensive evaluation of the market shares, growth strategies, and service offerings of prominent companies such as Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group (Switzerland), AbbVie, Inc. (US), WuXi AppTec (China), and others in the pharmaceutical contract development and manufacturing market.

Table of Contents:

1□INTRODUCTION□	32
1.1□STUDY OBJECTIVES□	32
1.2□MARKET DEFINITION□	33
1.2.1□INCLUSIONS AND EXCLUSIONS□	33
1.3□STUDY SCOPE□	33
1.3.1□MARKETS COVERED□	34
1.3.2□YEARS CONSIDERED□	35
1.3.3□CURRENCY CONSIDERED□	35
1.4□STAKEHOLDERS□	35
1.5□SUMMARY OF CHANGES□	36
1.5.1□IMPACT OF AI/GEN AI□	36
2□RESEARCH METHODOLOGY□	37
2.1□RESEARCH DATA□	37
2.1.1□SECONDARY DATA□	38
2.1.2□PRIMARY DATA□	39
2.2□MARKET SIZE ESTIMATION□	40
2.2.1□GLOBAL MARKET ESTIMATION□	41
2.2.2□INSIGHTS FROM PRIMARY SOURCES□	43
2.3□GROWTH RATE PROJECTIONS□	44

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.4	DATA TRIANGULATION	46
2.5	RESEARCH ASSUMPTIONS	48
2.6	RESEARCH LIMITATIONS	48
2.7	RISK ANALYSIS	48
3	EXECUTIVE SUMMARY	49
4	PREMIUM INSIGHTS	54
4.1	PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW	54
4.2	NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE & COUNTRY, 2023	55
4.3	NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE	56
4.4	PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER	56
4.5	PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	57
5	MARKET OVERVIEW	58
5.1	INTRODUCTION	58
5.2	MARKET DYNAMICS	58
5.2.1	DRIVERS	60
5.2.1.1	Increased investments in precision medicines	60
5.2.1.2	Rising demand for generic drugs	60
5.2.1.3	Need for affordable drug development	61
5.2.1.4	Favorable initiatives by contract development and manufacturing organizations	62
5.2.2	RESTRAINTS	63
5.2.2.1	Stringent regulatory requirements	63
5.2.3	OPPORTUNITIES	63
5.2.3.1	Emergence of cell and gene therapies	63
5.2.3.2	Growing inclination toward one-stop-shop model	65
5.2.3.3	Growth opportunities in emerging countries	65
5.2.3.4	Booming nuclear medicine market	66
5.2.4	CHALLENGES	66
5.2.4.1	Introduction of serialization	66
5.2.4.2	Intellectual property risk	66
5.3	PRICING ANALYSIS	67
5.3.1	INDICATIVE PRICING ANALYSIS, BY SERVICE	67
5.3.2	INDICATIVE PRICING ANALYSIS, BY REGION	67
5.4	VALUE CHAIN ANALYSIS	68
5.5	SUPPLY CHAIN ANALYSIS	70
5.6	ECOSYSTEM ANALYSIS	72
5.7	TECHNOLOGY ANALYSIS	74
5.7.1	KEY TECHNOLOGIES	75
5.7.1.1	Single-use bioprocessing systems	75
5.7.1.2	Continuous manufacturing	75
5.7.1.3	Advanced formulation technologies	76
5.7.2	COMPLEMENTARY TECHNOLOGIES	76
5.7.2.1	High-performance liquid chromatography	76
5.7.2.2	Mass spectrometry	76
5.7.2.3	Next-generation sequencing	77

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.7.2.4	Automation and robotics	77
5.7.2.5	Process analytical technology	78
5.7.3	ADJACENT TECHNOLOGIES	78
5.7.3.1	3D printing	78
5.7.3.2	Artificial intelligence and machine learning	79
5.8	PORTER'S FIVE FORCES ANALYSIS	79
5.8.1	THREAT OF NEW ENTRANTS	80
5.8.2	THREAT OF SUBSTITUTES	80
5.8.3	BARGAINING POWER OF SUPPLIERS	81
5.8.4	BARGAINING POWER OF BUYERS	81
5.8.5	INTENSITY OF COMPETITIVE RIVALRY	81
5.9	REGULATORY LANDSCAPE	81
5.9.1	REGULATORY SCENARIO	81
5.9.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	84
5.10	KEY CONFERENCES AND EVENTS, 2024-2025	88
5.11	KEY STAKEHOLDERS AND BUYING CRITERIA	89
5.11.1	KEY STAKEHOLDERS IN BUYING PROCESS	89
5.11.2	BUYING CRITERIA	90
5.12	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	91
5.13	ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS	91
5.14	INVESTMENT AND FUNDING SCENARIO	93
5.15	IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET	94
6	PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE	96
6.1	INTRODUCTION	97
6.2	PHARMACEUTICAL MANUFACTURING SERVICES	97
6.2.1	PHARMACEUTICAL API MANUFACTURING SERVICES	101
6.2.1.1	Rising cases of patent expiry to fuel market	101
6.2.2	PHARMACEUTICAL FDF MANUFACTURING SERVICES	105
6.2.2.1	Parenteral manufacturing services	109
6.2.2.1.1	Increasing demand for specialized manufacturing capabilities to support market growth	109
6.2.2.2	Tablet manufacturing services	112
6.2.2.2.1	Growing domestic production capacity in emerging markets to accelerate growth	112
6.2.2.3	Capsule manufacturing services	116
6.2.2.3.1	Rising adoption in pharmaceutical, nutraceutical, and cosmetic applications to stimulate growth	116
6.2.2.4	Oral liquid manufacturing services	119
6.2.2.4.1	Growing preference for oral liquids over powders to facilitate growth	119
6.2.2.5	Semi-solid manufacturing services	123
6.2.2.5.1	Rising prevalence of skin infections and burns to propel market	123
6.2.2.6	Other FDF manufacturing services	126
6.3	DRUG DEVELOPMENT SERVICES	130
6.3.1	INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH	130
?		
6.4	BIOLOGICS MANUFACTURING SERVICES	133
6.4.1	BIOLOGICS API MANUFACTURING SERVICES	137
6.4.1.1	Expanding offerings in cell line development and production to aid market growth	137
6.4.2	BIOLOGICS FDF MANUFACTURING SERVICES	140
6.4.2.1	Growing importance due to therapeutic potential to encourage growth	140

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.5	PACKAGING & LABELING SERVICES	144
6.5.1	INCREASING STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR MARKET GROWTH	144
6.6	FILL-FINISH SERVICES	147
6.6.1	SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO DRIVE MARKET	147
6.7	OTHER SERVICES	151
7	PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER	155
7.1	INTRODUCTION	156
7.2	BIG PHARMACEUTICAL COMPANIES	156
7.2.1	RIISING PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO MARKET GROWTH	156
7.3	SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES	160
7.3.1	NEED TO SAVE COSTS ON IN-HOUSE DRUG MANUFACTURING TO BOOST MARKET	160
7.4	GENERIC PHARMACEUTICAL COMPANIES	164
7.4.1	FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET	164
7.5	OTHER END USERS	168
8	PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION	171
8.1	INTRODUCTION	172
8.2	NORTH AMERICA	173
8.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	176
8.2.2	US	177
8.2.2.1	Presence of major pharmaceutical companies to drive market	177
8.2.3	CANADA	180
8.2.3.1	Favorable government support to sustain market growth	180
8.3	EUROPE	183
8.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	186
8.3.2	GERMANY	187
8.3.2.1	Free drug pricing policy to speed up market growth	187
8.3.3	UK	190
8.3.3.1	Favorable R&D funding scenario to augment growth	190
8.3.4	FRANCE	193
8.3.4.1	Booming life science research to fuel market	193
8.3.5	ITALY	196
8.3.5.1	Rising commercial drug development to favor growth	196
8.3.6	SWITZERLAND	199
8.3.6.1	Role as global pharmaceutical manufacturing hub to fuel market	199
8.3.7	POLAND	202
8.3.7.1	Universal health coverage and advanced infrastructure to encourage growth	202
8.3.8	SPAIN	205
8.3.8.1	Growing outsourcing of development and trial phases to boost market	205
8.3.9	REST OF EUROPE	208
8.4	ASIA PACIFIC	211
8.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	215
8.4.2	CHINA	216
8.4.2.1	Made in China 2025 initiative to aid market growth	216
8.4.3	INDIA	220

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.4.3.1	Favorable industrial environment and lower labor costs to drive market	220
8.4.4	AUSTRALIA	222
8.4.4.1	Strategic geographical location to foster growth	222
8.4.5	JAPAN	225
8.4.5.1	Growing geriatric population to augment growth	225
8.4.6	SOUTH KOREA	228
8.4.6.1	Initiatives for enhanced workforce, improved regulations, and R&D for new drugs to promote growth	228
8.4.7	REST OF ASIA PACIFIC	231
8.5	LATIN AMERICA	234
8.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	237
8.5.2	BRAZIL	238
8.5.2.1	Rapid patient enrolment and presence of highly experienced investigators for clinical trials to expedite growth	238
8.5.3	MEXICO	241
8.5.3.1	Surge in pharmaceutical goods export to promote growth	241
8.5.4	REST OF LATIN AMERICA	244
8.6	MIDDLE EAST	247
8.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST	250
8.6.2	GCC COUNTRIES	251
8.6.2.1	Kingdom of Saudi Arabia	254
8.6.2.1.1	Growing focus on enhanced healthcare expenditure to aid market growth	254
8.6.2.2	UAE	257
8.6.2.2.1	Growing population and healthcare spending to drive market	257
8.6.2.3	Other GCC Countries	260
8.6.3	REST OF MIDDLE EAST	263
8.7	AFRICA	266
8.7.1	RIISING CASES OF CANCER AND OTHER CHRONIC DISEASES TO FACILITATE GROWTH	266
8.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	269
9	COMPETITIVE LANDSCAPE	270
9.1	INTRODUCTION	270
9.2	KEY PLAYER STRATEGY/RIGHT TO WIN	270
9.3	REVENUE ANALYSIS	274
9.4	MARKET SHARE ANALYSIS	275
9.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	278
9.5.1	STARS	278
9.5.2	EMERGING LEADERS	278
9.5.3	PERVASIVE PLAYERS	278
9.5.4	PARTICIPANTS	278
9.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	280
9.5.5.1	Company footprint	280
9.5.5.2	Service footprint	281
9.5.5.3	End-user footprint	282
9.5.5.4	Region footprint	283
9.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	284
9.6.1	PROGRESSIVE COMPANIES	284
9.6.2	RESPONSIVE COMPANIES	284
9.6.3	DYNAMIC COMPANIES	284
9.6.4	STARTING BLOCKS	285

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	286
9.7	BRAND/SERVICE COMPARISON	288
9.7.1	THERMO FISHER SCIENTIFIC INC.	289
9.7.2	CATALENT, INC.	289
9.7.3	LONZA	289
9.7.4	SAMSUNG BIOLOGICS	289
9.7.5	WUXI APPTec	289
9.8	COMPANY VALUATION AND FINANCIAL METRICS	290
9.9	COMPETITIVE SCENARIO	291
9.9.1	SERVICE LAUNCHES	291
9.9.2	DEALS	292
9.9.3	EXPANSIONS	293
?		
10	COMPANY PROFILES	294
10.1	KEY PLAYERS	294
10.1.1	THERMO FISHER SCIENTIFIC INC.	294
10.1.1.1	Business overview	294
10.1.1.2	Services offered	295
10.1.1.3	Recent developments	296
10.1.1.3.1	Service launches	296
10.1.1.3.2	Deals	297
10.1.1.3.3	Expansions	298
10.1.1.4	MnM view	298
10.1.1.4.1	Key strengths	298
10.1.1.4.2	Strategic choices	298
10.1.1.4.3	Weaknesses and competitive threats	298
10.1.2	LONZA	299
10.1.2.1	Business overview	299
10.1.2.2	Services offered	301
10.1.2.3	Recent developments	302
10.1.2.3.1	Deals	302
10.1.2.4	MnM view	305
10.1.2.4.1	Key strengths	305
10.1.2.4.2	Strategic choices	305
10.1.2.4.3	Weaknesses and competitive threats	306
10.1.3	CATALENT, INC.	307
10.1.3.1	Business overview	307
10.1.3.2	Services offered	309
10.1.3.3	Recent developments	311
10.1.3.3.1	Service launches	311
10.1.3.3.2	Deals	311
10.1.3.3.3	Expansions	313
10.1.3.4	MnM view	314
10.1.3.4.1	Key strengths	314
10.1.3.4.2	Strategic choices	314
10.1.3.4.3	Weaknesses and competitive threats	314
10.1.4	WUXI APPTec	315

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1.4.1	Business overview	315
10.1.4.2	Services offered	317
10.1.4.3	Recent developments	317
10.1.4.3.1	Deals	317
10.1.4.3.2	Expansions	318
10.1.4.4	MnM view	319
10.1.4.4.1	Key strengths	319
10.1.4.4.2	Strategic choices	319
10.1.4.4.3	Weaknesses and competitive threats	319
10.1.5	WUXI BIOLOGICS	320
10.1.5.1	Business overview	320
10.1.5.2	Services offered	321
10.1.5.3	Recent developments	322
10.1.5.3.1	Deals	322
10.1.5.3.2	Expansions	323
10.1.6	SAMSUNG BIOLOGICS	324
10.1.6.1	Business overview	324
10.1.6.2	Services offered	325
10.1.6.3	Recent developments	325
10.1.6.3.1	Deals	325
10.1.6.3.2	Expansions	326
10.1.7	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	327
10.1.7.1	Business overview	327
10.1.7.2	Services offered	329
10.1.7.3	Recent developments	329
10.1.7.3.1	Deals	329
10.1.7.3.2	Expansions	330
10.1.8	EVONIK INDUSTRIES AG	331
10.1.8.1	Business overview	331
10.1.8.2	Services offered	333
10.1.8.3	Recent developments	333
10.1.8.3.1	Deals	333
10.1.8.3.2	Expansions	334
10.1.9	FUJIFILM HOLDINGS CORPORATION	335
10.1.9.1	Business overview	335
10.1.9.2	Services offered	336
10.1.9.3	Recent developments	338
10.1.9.3.1	Deals	338
10.1.9.3.2	Expansions	339
10.1.10	ABBVIE INC.	340
10.1.10.1	Business overview	340
10.1.10.2	Services offered	341
10.1.10.3	Recent developments	342
10.1.10.3.1	Deals	342
10.1.10.3.2	Expansions	343
10.1.11	SIEGFRIED HOLDING AG	344
10.1.11.1	Business overview	344

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1.11.2	Services offered	345
10.1.11.3	Recent developments	346
10.1.11.3.1	Deals	346
10.1.11.3.2	Expansions	346
10.1.12	MERCK KGAA	347
10.1.12.1	Business overview	347
10.1.12.2	Services offered	349
10.1.12.3	Recent developments	349
10.1.12.3.1	Deals	349
10.1.12.3.2	Expansions	350
10.1.13	ALMAC GROUP	351
10.1.13.1	Business overview	351
10.1.13.2	Services offered	351
10.1.13.3	Recent developments	353
10.1.13.3.1	Deals	353
10.1.13.3.2	Expansions	353
10.1.14	CHARLES RIVER LABORATORIES	355
10.1.14.1	Business overview	355
10.1.14.2	Services offered	355
10.1.14.3	Recent developments	356
10.1.14.3.1	Deals	356
10.1.14.3.2	Expansions	356
10.1.15	ASYMCHEM INC.	357
10.1.15.1	Business overview	357
10.1.15.2	Services offered	358
10.1.15.3	Recent developments	359
10.1.15.3.1	Deals	359
10.1.15.3.2	Expansions	359
10.1.16	VETTER PHARMA	360
10.1.16.1	Business overview	360
10.1.16.2	Services offered	360
10.1.16.3	Recent developments	361
10.1.16.3.1	Deals	361
10.1.16.3.2	Expansions	361
10.1.17	ALCAMI CORPORATION	362
10.1.17.1	Business overview	362
10.1.17.2	Services offered	363
10.1.17.3	Recent developments	363
10.1.17.3.1	Deals	363
10.1.17.3.2	Expansions	364
10.2	OTHER PLAYERS	365
10.2.1	PIRAMAL PHARMA SOLUTIONS	365
10.2.2	SYNGENE INTERNATIONAL LIMITED	366
10.2.3	CAMBREX CORPORATION	367
10.2.4	JUBILANT BIOSYS LTD.	368
10.2.5	YUHAN CORPORATION	369
10.2.6	PIERRE FABRE GROUP	370

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.2.7	PFIZER CENTREONE	371
10.2.8	DELPHARM	372
10.2.9	FRONTAGE LABS	373
10.2.10	SHARP SERVICES, LLC	374
10.2.11	GRAND RIVER ASEPTIC MANUFACTURING	375
11	APPENDIX	376
11.1	DISCUSSION GUIDE	376
11.2	KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	380
11.3	CUSTOMIZATION OPTIONS	382
11.4	RELATED REPORTS	383
11.5	AUTHOR DETAILS	384

Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule, Oral Liquid), Biologics (API, FDF), Packaging & Labelling, Fill-finish), End Users - Global Forecasts to 2029

Market Report | 2024-08-02 | 385 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-20

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com